KR101745025B1 - 항-ｍｓｔ１ｒ 항체 및 그의 용도 - Google Patents

항-ｍｓｔ１ｒ 항체 및 그의 용도 Download PDF

Info

Publication number
KR101745025B1
KR101745025B1 KR1020117018586A KR20117018586A KR101745025B1 KR 101745025 B1 KR101745025 B1 KR 101745025B1 KR 1020117018586 A KR1020117018586 A KR 1020117018586A KR 20117018586 A KR20117018586 A KR 20117018586A KR 101745025 B1 KR101745025 B1 KR 101745025B1
Authority
KR
South Korea
Prior art keywords
ser
leu
val
gly
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117018586A
Other languages
English (en)
Korean (ko)
Other versions
KR20110117677A (ko
Inventor
레이미 가와이다
도시아키 오츠카
도시노리 아가츠마
필립 로들리
잔드라 밀러
울리케 슈베르트
Original Assignee
다이이찌 산쿄 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이이찌 산쿄 가부시키가이샤 filed Critical 다이이찌 산쿄 가부시키가이샤
Publication of KR20110117677A publication Critical patent/KR20110117677A/ko
Application granted granted Critical
Publication of KR101745025B1 publication Critical patent/KR101745025B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020117018586A 2009-02-10 2010-02-10 항-ｍｓｔ１ｒ 항체 및 그의 용도 Expired - Fee Related KR101745025B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15141109P 2009-02-10 2009-02-10
US61/151,411 2009-02-10
PCT/JP2010/052479 WO2010093055A1 (en) 2009-02-10 2010-02-10 Anti-mst1r antibodies and uses thereof

Publications (2)

Publication Number Publication Date
KR20110117677A KR20110117677A (ko) 2011-10-27
KR101745025B1 true KR101745025B1 (ko) 2017-06-20

Family

ID=42227811

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117018586A Expired - Fee Related KR101745025B1 (ko) 2009-02-10 2010-02-10 항-ｍｓｔ１ｒ 항체 및 그의 용도

Country Status (18)

Country Link
US (1) US9403909B2 (https=)
EP (1) EP2396084B1 (https=)
JP (1) JP5714511B2 (https=)
KR (1) KR101745025B1 (https=)
CN (1) CN102438702B (https=)
AU (1) AU2010214301B2 (https=)
BR (1) BRPI1007979A2 (https=)
CA (1) CA2752136C (https=)
CO (1) CO6420322A2 (https=)
ES (1) ES2583281T3 (https=)
IL (1) IL214527A0 (https=)
MX (1) MX2011008456A (https=)
NZ (1) NZ594452A (https=)
RU (1) RU2534890C2 (https=)
SG (2) SG2014009195A (https=)
TW (1) TWI480050B (https=)
WO (1) WO2010093055A1 (https=)
ZA (1) ZA201105725B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356749B (es) * 2012-04-27 2018-06-12 Daiichi Sankyo Co Ltd Anticuerpo anti-homologo 4 de roundabout (robo4).
TWI909341B (zh) 2015-09-24 2025-12-21 日商第一三共股份有限公司 抗garp抗體及其製造方法及用途
EP3504244A4 (en) 2016-08-26 2020-08-19 Agency for Science, Technology and Research MACROPHAGE-STIMULATING PROTEIN RECEPTOR ANTIBODIES (OR OF NANTAIS ORIGINAL RON-RECEPTOR) AND THEIR USES
MX2022001812A (es) 2019-08-12 2022-03-11 Regeneron Pharma Variantes del receptor estimulante de macrofagos 1 (mst1r) y sus usos.
WO2021066751A1 (en) * 2019-10-02 2021-04-08 Aslan Pharmaceuticals Pte. Ltd. Antigen specific binding domains and antibody molecules
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
CA2566647A1 (en) * 2004-05-13 2005-12-22 Imclone Systems Incorporated Inhibition of macrophage-stimulating protein receptor (ron)
US20060073256A1 (en) * 2004-06-15 2006-04-06 Frederic Destaillats Self-foaming liquid creamers and processes
JP2008512352A (ja) * 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
UY31478A1 (es) * 2007-11-21 2009-07-17 Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
MX2010008025A (es) * 2008-01-22 2010-08-04 Biogen Idec Inc Anticuerpos ron y usos de los mismos.

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cancer 109(6): 1030-1039(2007.03.15.)
Cancer Res. 66(18): 9162-9170(2006.09.15.)*
Hybridoma 17(6): 541-551(1998.12.)
NCBI GenBank Accession No. CAA49634(2005.04.18.)*

Also Published As

Publication number Publication date
EP2396084B1 (en) 2016-05-11
AU2010214301A1 (en) 2011-09-01
US9403909B2 (en) 2016-08-02
KR20110117677A (ko) 2011-10-27
WO2010093055A1 (en) 2010-08-19
TW201036635A (en) 2010-10-16
SG173196A1 (en) 2011-08-29
IL214527A0 (en) 2011-09-27
US20120034215A1 (en) 2012-02-09
HK1164193A1 (zh) 2012-09-21
CO6420322A2 (es) 2012-04-16
RU2534890C2 (ru) 2014-12-10
RU2011137405A (ru) 2013-03-20
TWI480050B (zh) 2015-04-11
JP5714511B2 (ja) 2015-05-07
EP2396084A1 (en) 2011-12-21
ZA201105725B (en) 2012-04-25
MX2011008456A (es) 2011-09-26
AU2010214301B2 (en) 2016-11-10
SG2014009195A (en) 2014-04-28
BRPI1007979A2 (pt) 2017-10-03
ES2583281T3 (es) 2016-09-20
CN102438702A (zh) 2012-05-02
JP2012517223A (ja) 2012-08-02
CA2752136A1 (en) 2010-08-19
CN102438702B (zh) 2016-03-02
CA2752136C (en) 2016-03-15
NZ594452A (en) 2013-01-25

Similar Documents

Publication Publication Date Title
JP7328658B2 (ja) 抗ｐｄ－ｌ１／抗４－１ｂｂ二重特異性抗体およびその使用
CN112154157B (zh) 抗ror1抗体及其用途
CN107001472B (zh) 对cd73具有特异性的结合分子及其用途
AU2003216748B2 (en) Novel anti-IGF-IR antibodies and uses thereof
CN102421802B (zh) 人源化的axl抗体
CN108699150B (zh) 治疗性抗-cd9抗体
US9676846B2 (en) Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
KR20170137073A (ko) 항-인간 ｎｏｔｃｈ4 항체
EP2139920A1 (en) Human anti cd166 antibody binding human tumor cells
CN104936984A (zh) 特异性结合人和小鼠l1cam的抗体及其用途
KR101745025B1 (ko) 항-ｍｓｔ１ｒ 항체 및 그의 용도
KR20180016320A (ko) 프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도
KR102887692B1 (ko) 항-bcam 항체 또는 그의 항원 결합 단편
CN114729013B (zh) 抗cd22抗体及其用途
CN110964107B (zh) Met结合分子、其组合和用途
KR20230158058A (ko) 시알산-결합 ig-유사 렉틴 15에 특이적인 항체 및 이의 용도
KR20140138533A (ko) 항 igf-1r 단일클론 항체 및 이를 포함하는 암치료용 조성물
CN114641307A (zh) 抗cd19抗体及其用途
HK1164193B (en) Anti-mst1r antibodies and uses thereof
EA045275B1 (ru) Анти-pd-l1/анти-4-1bb биспецифические антитела и их применения

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200602

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200602